Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement  of the Convening of the General Meeting in Frankfurt am Main on 14.07.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 14.07.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 14.07.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip: https://g.foolcdn.com/editorial/images/734634/patient-talking-with-a-physician.jpg
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least

CVS Stock Just Hit a 52-Week Low. Is It Time to Buy?: https://g.foolcdn.com/editorial/images/734611/pharmacists-looking-at-pills-in-bottle.jpg
CVS Stock Just Hit a 52-Week Low. Is It Time to Buy?

CVS Health (NYSE: CVS) is a busy company. It runs the nation's largest drugstore chain with nearly 10,000 locations; it also manages prescription drug plans for employers and insurers; and, through

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?: https://g.foolcdn.com/editorial/images/734429/physician-giving-a-high-five-to-a-young-patient.jpg
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Over the past year, the company's shares are up by 17%. And Wall Street continues to be

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade: https://g.foolcdn.com/editorial/images/734212/patient-taking-medicine.jpg
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade

People saving for retirement often dream of crossing the $1 million milestone. While it is far from obvious that this amount is enough to live out the rest of one's life comfortably, it is still a

3 Dividend Stocks You Can Buy Without Any Hesitation: https://g.foolcdn.com/editorial/images/734743/stock-market-person-looking-at-computer-charts.jpg
3 Dividend Stocks You Can Buy Without Any Hesitation

Decisions, decisions. Every investor has to make them. The good news is that some decisions aren't difficult. Three Motley Fool contributors identified dividend stocks that should be easy buy

Could AI Boost Growth at Medtronic?: https://g.foolcdn.com/editorial/images/734697/gettyimages-1191849990.jpg
Could AI Boost Growth at Medtronic?

Medtronic (NYSE: MDT) has grown revenue over the years thanks to its solid portfolio of medical devices. The company sells devices worldwide in the areas of diabetes, cardiovascular, neuroscience

Why Shares of BioNTech Rose Friday: https://g.foolcdn.com/editorial/images/734975/vaccine-covid-coronavirus-pandemic-health.jpg
Why Shares of BioNTech Rose Friday

Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its

Why Victoria's Secret Stock Fell This Week: https://g.foolcdn.com/editorial/images/734877/online-shopping-with-credit-card-at-home.jpg
Why Victoria's Secret Stock Fell This Week

Victoria's Secret (NYSE: VSCO) shareholders lost ground to the market this week. Shares fell 14% through Thursday trading, compared to a 0.4% increase in the S&P 500. This drop added to a tough year

Why Biohaven Stock Caught Fire This Week: https://g.foolcdn.com/editorial/images/734868/pills-dollar-symbol.jpg
Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The

Is Amgen a Good Dividend Stock?: https://g.foolcdn.com/editorial/images/734690/dividend-concept.jpg
Is Amgen a Good Dividend Stock?

Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock. The company has raised its payout for 12 straight years, free cash flows have remained steady at a little over

Should Income Investors Buy This Soon-to-Be Dividend King?: https://g.foolcdn.com/editorial/images/734446/a-doctor-and-patient-at-an-appointment.jpg
Should Income Investors Buy This Soon-to-Be Dividend King?

Imagine spending a lifetime building your investment portfolio only to worry about whether you will outlive the balance in your investment accounts.

If you are exclusively buying growth stocks with

Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/734329/getty-happy-person-indoors-smiling.jpg
Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now

Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. No investment has a guaranteed outcome. However, if you

Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?: https://g.foolcdn.com/editorial/images/734260/businessman-with-a-chart-looking-at-his-computer.jpg
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?

Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Panic has been setting in

Why Horizon Technology Finance Stock Plummeted Today: https://g.foolcdn.com/editorial/images/734620/person-at-desk-in-front-of-laptop-with-hands-on-face.jpg
Why Horizon Technology Finance Stock Plummeted Today

Not for the first time this year, Horizon Technology Finance (NASDAQ: HRZN) is tapping the public markets for a fresh round of capital-raising. Investors clearly didn't consider that to be good

Why Pfizer Stock Is Perking Up Today: https://g.foolcdn.com/editorial/images/734591/happy-investor.jpg
Why Pfizer Stock Is Perking Up Today

Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. The drugmaker's stock is trending higher despite every major U.S. stock index

Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer: https://g.foolcdn.com/editorial/images/733886/getty-happy-couple-reassured-relief-relieved.jpg
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer

While many investors set a retirement goal of $1 million or more, there are many factors that will impact the amount you ultimately have set away for your later years. The length of time you spend

Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?: https://g.foolcdn.com/editorial/images/734257/businessperson-giving-a-presentation.jpg
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?

Weight-loss drugs have been surging in popularity over the past year. Even Novo Nordisk's Ozempic, which isn't approved to treat weight loss, has made for a hot trend on social media, with people

2 Incredible Growth Stocks to Buy Before the Next Bull Market: https://g.foolcdn.com/editorial/images/734326/confident-happy-businessman-taking-notes.jpg
2 Incredible Growth Stocks to Buy Before the Next Bull Market

You're not alone if you're waiting with eager anticipation for the next prolonged bull market. The stock market has clocked its fair share of up and down days in the first several months of 2023

The Best Stocks to Invest $5,000 in Right Now: https://g.foolcdn.com/editorial/images/734063/nurse-tending-patient-in-intensive-care.jpg
The Best Stocks to Invest $5,000 in Right Now

You don't have to outthink the market or take big risks to profit off an investment. There are plenty of good healthcare stocks with strong momentum and solid financials that make great long-term

CRISPR Therapeutics: A Galaxy's Worth of Deep Value: https://g.foolcdn.com/editorial/images/734394/galaxy.jpg
CRISPR Therapeutics: A Galaxy's Worth of Deep Value

CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the

2 Ultra-Safe Dividend Stocks to Load Up On Right Now: https://g.foolcdn.com/editorial/images/734102/band-aid-piggybank.jpg
2 Ultra-Safe Dividend Stocks to Load Up On Right Now

If your stock portfolio hasn't fully recovered from the 2022 bear market, you're definitely not alone. Even after the fairly strong rally in growth and value stocks during the first half of 2023

Is It Too Late to Buy Medtronic's Stock?: https://g.foolcdn.com/editorial/images/734281/doctor-examining-a-patient.jpeg
Is It Too Late to Buy Medtronic's Stock?

History has shown that purchasing stocks in resilient companies that can weather market highs and lows is an effective long-term investment strategy. 

Ireland-based Medtronic (NYSE: MDT), a major

Why Shares of Iovance Biotherapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/734441/doctors-white-coat-healthcare.jpg
Why Shares of Iovance Biotherapeutics Jumped Tuesday

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?: https://g.foolcdn.com/editorial/images/734103/gettyimages-1139704348.jpg
Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer (NYSE: PFE) brought in enormous levels of revenue over the past couple of years thanks to its coronavirus vaccine and treatment. The company also continues to benefit from sales of